查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1864559

性行為感染傳染病診斷市場按診斷測試類型、病原體類型、最終用戶類型、檢體類型、技術類型和產品類型分類－2025年至2032年全球預測

Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，性行為感染傳染病診斷市場將成長至 1,821.1 億美元，複合年成長率為 6.19%。

關鍵市場統計數據
基準年 2024 1125.6億美元
預計年份：2025年 1194.2億美元
預測年份 2032 1821.1億美元
複合年成長率 (%) 6.19%

本文簡要概述了技術創新、分散式醫療服務和不斷變化的臨床重點如何重塑臨床環境和公共衛生領域的性行為感染診斷。

性行為感染感染的診斷領域正經歷快速的技術和營運變革，這影響著診斷服務提供者、實驗室網路、臨床醫生和公共衛生機構。分子技術、攜帶式檢測平台和整合診斷工作流程的進步正在重塑感染疾病的檢測方式、結果的溝通方式以及診療路徑的建構方式。同時，強調分散式檢查和患者自主性的不斷發展的診療模式，推動了對就地檢驗和自測方案的需求，進而促使採購、品質保證和監管重點發生轉變。

臨床醫生和公共衛生領導者正在應對不斷變化的病原體情況、不斷擴大的多重診斷覆蓋範圍，以及對快速、可操作結果以支持治療和接觸者追蹤的需求。診斷試劑生產商必須應對複雜的檢體類型，包括血液、各種拭子和尿液，每種樣本都有不同的分析前和分析要求。同時，實驗室服務正在將自動化、次世代定序和先進的免疫檢測整合到其工作流程中，以提高通量和診斷準確性。本導言（構成執行摘要的其餘部分）概述了推動創新的相互關聯的因素、影響技術應用的營運壓力，以及領導者為保持競爭力和臨床相關性而必須應對的策略挑戰。

分子生物學、微流體和分散式醫療保健模式的創新正在融合，從根本上改變性行為感染傳染病 (STD) 的診斷和監測實踐。

性行為感染感染的診斷格局正經歷一場變革，這主要得益於分子技術的突破、快速攜帶式檢測方法的成熟以及先進生物資訊學方法的整合。新興的基於 CRISPR 的診斷技術以及核酸擴增技術的進步，包括 PCR 和次世代定序，正在提高對更多病原體的檢測靈敏度和特異性。同時，微流體實驗室晶片解決方案和改進的免疫檢測方法（例如，增強型側向流動檢測）正在實現真正的即時檢測流程，從而在傳統實驗室之外也能提供可靠的檢測結果。

這些技術進步與醫療服務模式的變革相吻合。居家檢測模式和直接面對消費者的通路的擴展，在提升病患就醫便利性的同時，也為結果解讀、確診檢測和照護協調帶來了新的挑戰。為此，診斷實驗室正在採用自動化和多重檢測平台，以實現高通量篩檢和全面的病原體檢測。公共衛生機構正在利用可互通的數據系統和基因組監測，加強對疫情爆發和抗藥性模式的監測，凸顯了將診斷結果與流行病學資訊結合的重要性日益凸顯。這些變化共同重塑了整個診斷生態系統的競爭優勢、監管重點和夥伴關係模式。

評估2025年美國關稅調整對性傳染病診斷相關人員的供應鏈和採購的實際影響

2025年美國關稅政策對診斷供應鏈和採購管道產生了實際的營運和策略影響。進口設備、試劑和特殊組件的關稅調整增加了許多供應商的到岸成本，迫使製造商和經銷商重新評估籌資策略、庫存管理政策和定價模式。為此，一些企業加快了本土化生產，實現了供應鏈多元化，並探索了其他組件供應商，以期維持利潤率並按時交付。

關稅引發的成本變化正在影響資本設備和耗材的採購決策，並波及臨床和公共衛生領域。實驗室和醫院正優先考慮總體擁有成本分析以及整合檢測項目的平台，以降低單位成本。同時，試劑和套件供應商正在修訂分銷協議，並探索區域製造合作夥伴關係，以減輕關稅影響帶來的複雜性和風險。因此，各方更重視加強供應鏈韌性、發展策略供應商關係，並採取兼顧成本控制、維持診斷品質和保障患者照護連續性的採購方式。

透過對診斷方式、病原體標靶、終端用戶環境、檢體要求、平台技術和產品類型進行深度細分，提供可操作的市場洞察。

細分市場分析揭示了不同診斷方法、病原體標靶、終端用戶環境、檢體類型、技術平台和產品形式所帶來的需求差異和技術適用性。基於診斷測試類型，傳統檢測仍然是高通量生物標記、血液和尿液檢查工作流程的核心，而分子檢測（例如次世代定序、核酸增幅檢查和聚合酵素鏈鎖反應）則為複雜病原體的檢測提供了黃金標準靈敏度。可攜式分析儀、快速診斷測試和自我測試檢測套組等照護現場形式正在擴大檢測範圍，但需要進行嚴格的檢驗，以確保其準確性與實驗室方法相當。

依病原體分類，可以發現針對不同病原體的臨床和商業需求各有重點：細菌感染疾病（如披衣菌感染、淋病和梅毒）；病毒感染疾病（如B型肝炎、單純皰疹、HIV 和 HPV）；寄生蟲感染疾病（如滴蟲病）；以及商業性感染疾病（如念珠菌症）。按最終用戶分類，診斷實驗室（包括病理實驗室和研究機構）優先考慮檢測通量和多重檢測能力，而面向消費者的直接檢測和透過線上藥局提供的居家照護管道則強調易用性和清晰的後續指導。醫院和診所需要快速報告檢測結果並將其整合到電子健康記錄中，而公共衛生部門則需要強大的報告功能和監測系統互通性。

檢體類型細分突出了血液來源的血漿和血清、生殖器、口腔和直腸拭子檢體以及尿液檢體（包括初段尿和中段尿）各自獨特的檢體製備管理和套件設計考慮。技術細分突出了基於 CRISPR 的診斷方法、免疫檢測（如 ELISA 和側向層析）、實驗室晶片微流體技術以及光譜技術（如紅外光譜和拉曼光譜）在輔助分析中日益成長的重要性。產品類型細分區分了耗材（如移液器和試管）、設備（如分析儀和自動化系統）以及用於細菌和病毒診斷的試劑和試劑套件，每種產品都有不同的採購週期和監管途徑。這些相互交織的細分層級有助於制定市場推廣策略、臨床檢驗重點和產品開發藍圖。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和基礎設施因素如何影響診斷方法的採用、取得和夥伴關係模式

區域趨勢正在影響美洲、歐洲、中東、非洲和亞太地區的需求模式、監管要求和夥伴關係機會。在美洲，臨床網路和公共衛生機構正在部署集中式檢測平台並擴大社區檢測範圍，以解決在獲取醫療服務和快速診斷方面持續存在的差距。同時，保險覆蓋政策和不斷變化的報銷框架正在影響新型分子診斷和照護現場方案的普及速度。

在歐洲、中東和非洲地區，不同的管理體制和實驗室基礎設施導致高複雜度檢測和分散式快速檢測的普及程度存在差異。該地區的公共衛生重點在於監測、抗菌素抗藥性監測和公平獲取醫療服務，因此需要性能可靠、成本低廉且具有高現場應用價值的診斷技術。在亞太地區，強大的生產能力、龐大且多元化的患者群體以及數位化醫療的快速普及，都促進了整合診斷平台的加速應用以及試劑和耗材的在地化生產。總而言之，這些區域特徵決定了打入市場策略、經銷夥伴以及服務和支援能力的本地化，以滿足特定的臨床和監管要求。

結合平台整合、監管覆蓋和創新技術合作，採取競爭與合作並重的企業策略，以確立在性傳染病診斷領域的領先地位。

主要企業層面洞察聚焦於策略定位、產品組合廣度和能力，這些因素共同促成了企業在競爭激烈的診斷生態系統中的差異化。領先的儀器製造商優先考慮平台整合，提供支援多重檢測並可與實驗室資訊系統整合的分析儀和自動化系統。試劑和套件供應商專注於針對細菌和病毒診斷的檢驗病原體特異性檢測方法，同時投資於供應鏈的穩健性和多司法管轄區的監管註冊。新興企業優先考慮顛覆性技術，例如基於 CRISPR 的檢測方法、實驗室晶片微流體技術和新型光譜學方法，並尋求臨床檢驗夥伴關係和有針對性的試點部署以建立信譽。

通路和服務模式正日益成為重要的差異化因素。能夠提供靈活採購方案、培訓和技術支援以及便於向公共衛生機構報告的資料管理服務的公司，往往更容易獲得醫療機構的青睞。同時，那些為消費者產品建立清晰推廣路徑（包括支援確診檢測和醫療合作）的公司，則更有利於抓住家庭檢測管道的需求。成熟製造商與創新Start-Ups之間的策略合作，例如共同開發和分銷協議，有助於將新型診斷技術快速轉化為可擴展的產品，同時降低技術和監管風險。

為製造商、實驗室和公共衛生合作夥伴提供切實可行的策略重點，以加速診斷技術的普及應用，並建立一個具有韌性的診斷體系。

產業領導者應抓住新機遇，推動一系列協作行動，協調產品開發、監管策略、供應鏈韌性和商業模式。優先投資於兼具實驗室級性能和分散式環境實用性的技術，從而實現平台在醫院、社區診所和消費者場所的部署，同時保持臨床可靠性。同時，應制定清晰的循證計劃，重點關注實際應用效能、驗證性檢測途徑和成本效益，以支持支付方和採購決策。

我們將進一步實現供應商多元化，並在條件允許的情況下將零件採購轉移到近岸地區，以降低關稅波動風險，並提高應對力。我們將制定分層市場推廣策略，針對診斷實驗室、醫院、公共衛生部門和居家照護管道最佳化通訊和支持，提供包括培訓、整合協助和數據報告在內的捆綁式服務。最後，我們將與公共衛生組織、學術機構和技術創新者建立策略合作夥伴關係，以加速檢驗研究並擴大監測應用，從而增強臨床信心，並為長期應用奠定基礎。

嚴謹的混合方法研究過程（結合從業者訪談、技術文獻回顧和交叉檢驗的分析框架）確保了診斷結果的可靠性。

本報告的調查方法結合了第一手資料和第二手資料，旨在全面了解性行為感染）診斷的現狀。第一手資料包括與臨床實驗室主任、感染疾病專家、公共衛生負責人和診斷行業高管進行結構化訪談和對話，以了解當前的實踐、推廣障礙和戰略重點。這些第一手資料促成了對臨床和消費者管道的技術準備、營運限制和推廣促進因素的定性評估。

二次研究回顧了同儕審查文獻、監管指導文件、會議報告和產品技術規範，以檢驗技術描述、檢體處理要求和監管路徑。對一級研究和二次研究進行交叉檢驗，確保結論既反映了實務經驗，也體現了技術證據。分析架構著重於技術成熟度、臨床效用、供應鏈因素和商業化動態。盡可能地，對來自多個資訊來源的證據進行三角驗證，以減少偏差並增強本報告結論的可信度。

全面分析創新、業務連續性和策略合作如何決定哪些診斷產品能夠獲得臨床應用並創造公共衛生價值。

總之，性行為感染傳染病診斷正處於轉折點。技術進步、不斷演進的診療模式以及供應鏈現狀正在相互交織，重新定義臨床工作流程和市場機會。分子檢測、基於 CRISPR 的平台、微流體技術和先進免疫檢測的創新，正在拓展中心實驗室和分散式檢查環境的能力。因此，相關人員必須權衡快速靈敏診斷的前景與檢驗、監管合規以及融入診療路徑等實際挑戰。

那些積極主動地將產品開發與終端用戶需求相結合、加強供應鏈以應對關稅和採購衝擊、並建立連接臨床、公共衛生和消費者環境的夥伴關係關係的領導者，將更有能力將技術的潛力轉化為持續的臨床成果。本摘要中提出的建議為指導投資、合作和營運決策提供了策略基礎，這些決策將塑造性行為感染檢測和管理的未來。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將快速照護現場分子檢測整合到社區醫療保健機構中，以縮短診斷時間
  • 開發用於同時檢測多種性行為感染傳染病（包括新出現的病原體）的多重檢測平台
  • 為高風險族群引入用於分散性行為感染傳染病篩檢的自採集和居家檢體採集試劑套件
  • 引入人工智慧驅動的數據分析，建構性行為感染傳染病爆發預測模型，並制定個人化治療策略
  • 擴大基於 CRISPR 的診斷技術在披衣菌感染和淋病高靈敏度和特異性檢測的應用
  • 透過遠端醫療提供者和診斷試劑生產商之間的合作，擴大遠距性行為感染檢測的覆蓋範圍。
  • 重點研究抗藥性檢測方法，以指導抗藥性感染疾病的標靶治療

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章性行為感染傳染病診斷市場（依診斷檢驗類型分類）

  • 實驗室檢測
    • 基於生物標記的檢測
    • 血液檢查
    • 尿液檢查
  • 分子檢測
    • 次世代定序
    • 核酸增幅檢查（NAATs）
    • 聚合酵素鏈鎖反應（PCR）
  • 就地檢驗
    • 攜帶式分析儀
    • 快速診斷測試
    • 自測檢測套組

第9章 依病原體類型性行為感染傳染病診斷市場

  • 細菌性行為感染傳染病
    • 披衣菌感染
    • 淋病
    • 梅毒
  • 黴菌性性行為感染感染
    • 念珠菌症
  • 寄生性行為感染傳染病
    • 滴蟲病
  • 病毒性行為感染傳染病
    • B型肝炎
    • 單純皰疹病毒
    • 人類免疫力缺乏病毒（HIV）
    • 人類乳突病毒（HPV）

第10章 以最終使用者類型分類的性行為感染傳染病診斷市場

  • 診斷實驗室
    • 病理實驗室
    • 研究所
  • 居家醫療環境
    • 直接面對消費者的測試
    • 網路藥房
  • 醫院和診所
    • 醫療設施
    • 門診部
  • 公共衛生部門
    • 社區醫療中心
    • 州衛生部門

第11章 依檢體類型分類的性行為感染傳染病診斷市場

  • 血液樣本
    • 電漿
    • 血清
  • 拭子檢體
    • 生殖器拭子
    • 口腔拭子
    • 直腸拭子
  • 尿液檢體
    • 第一次尿液
    • 中段尿

第12章 依技術類型性行為感染傳染病診斷市場

  • 基於CRISPR的診斷
    • CRISPR-Cas
  • 免疫檢測
    • ELISA
    • 橫向流動化驗
  • 微流體技術
    • 晶片實驗室
  • 光譜學
    • 紅外線的
    • 拉曼光譜

第13章性行為感染傳染病診斷市場（依產品類型分類）

  • 消耗品
    • 移液器
    • 管子
  • 裝置
    • 分析器
    • 自動化系統
  • 試劑和套件
    • 細菌性行為感染傳染病檢測套件
    • 病毒性性性行為感染檢測套件

第14章 各地區性行為感染傳染病診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章性行為感染傳染病診斷市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國性行為感染傳染病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Astra Biotech Gmbh
    • Becton Dickinson and company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • Daye Limited
    • Diasorin SpA
    • F. Hoffmann-La Roche Ltd
    • Geneproof
    • Hologic Inc.
    • Jiangsu BioPerfectus Technologies Co., Ltd
    • Liferiver Bio-Tech Corp.
    • MedMira Inc
    • Meridian Bioscience Inc.
    • Mylab Discovery Solutions Pvt. Ltd.
    • OraSure Technologies, Inc.
    • Qiagen Inc
    • Quest Consumer Inc.
    • Sansure Biotech Inc.
    • Seegene Inc.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
Product Code: MRR-6D54EA0F9447

The Sexually Transmitted Disease Diagnostics Market is projected to grow by USD 182.11 billion at a CAGR of 6.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 112.56 billion
Estimated Year [2025] USD 119.42 billion
Forecast Year [2032] USD 182.11 billion
CAGR (%) 6.19%

A concise orientation to how technological innovation, decentralized care delivery, and changing clinical priorities are reshaping STD diagnostics across clinical and public health settings

The sexually transmitted disease diagnostics landscape is undergoing rapid technical and operational shifts that affect diagnostics providers, laboratory networks, clinical practitioners, and public health entities. Advances in molecular technologies, portable testing platforms, and integrated diagnostics workflows are reshaping how infections are detected, how results are delivered, and how care pathways are constructed. Meanwhile, evolving care models that emphasize decentralized testing and greater patient autonomy are increasing demand for point-of-care and self-testing options, which in turn changes procurement, quality assurance, and regulatory priorities.

Clinicians and public health leaders are adapting to changes in pathogen prevalence, the expanding scope of multiplex diagnostics, and the need for faster, actionable results to support treatment and contact tracing. Diagnostic manufacturers must navigate a complex array of sample types, including blood, various swabs, and urine, each with distinct pre-analytic and analytic requirements. At the same time, laboratory services are integrating automation, next-generation sequencing, and advanced immunoassays into workflows to improve throughput and diagnostic certainty. This introduction frames the remainder of the executive summary by outlining the intersecting drivers of innovation, the operational pressures shaping adoption, and the strategic questions leaders must address to remain competitive and clinically relevant.

How converging innovations in molecular biology, microfluidics, and decentralized care models are fundamentally altering STD diagnostics and surveillance practices

The landscape for sexually transmitted disease diagnostics is shifting in transformative ways, driven by breakthroughs in molecular techniques, the maturation of rapid and portable testing, and the incorporation of advanced bioinformatic methods. Emerging CRISPR-based diagnostics and improvements in nucleic acid amplification, including PCR and next-generation sequencing, are increasing sensitivity and specificity across a wider range of pathogens. Concurrently, microfluidic lab-on-a-chip solutions and refined immunoassays such as enhanced lateral flow formats are enabling true point-of-care workflows that deliver reliable results outside traditional laboratories.

These technical advances coincide with changes in care delivery. Home-based testing models and direct-to-consumer distribution channels are expanding patient access while introducing new considerations around result interpretation, confirmatory testing, and linkage to care. Diagnostic laboratories are responding by adopting automation and multiplex platforms that support high-throughput screening and comprehensive pathogen panels. Public health entities are leveraging interoperable data systems and genomic surveillance to monitor outbreaks and resistance patterns, which underscores the growing importance of integrating diagnostic outputs with epidemiologic intelligence. Together, these shifts are redefining competitive advantage, regulatory priorities, and partnership models across the diagnostics ecosystem.

Evaluating the practical supply chain and procurement consequences of the United States tariff adjustments enacted in 2025 on STD diagnostics stakeholders

United States tariff policies enacted in 2025 have introduced tangible operational and strategic implications across diagnostic supply chains and procurement channels. Tariff adjustments on imported instruments, reagents, and specialized components have increased landed costs for many suppliers, prompting manufacturers and distributors to reassess sourcing strategies, inventory policies, and pricing models. In response, several organizations have accelerated onshoring initiatives, diversified supplier bases, and explored alternative component suppliers to preserve margin and maintain delivery timelines.

These tariff-induced cost dynamics ripple through clinical and public health settings by influencing purchasing decisions for capital equipment and recurring consumables. Laboratories and hospitals are prioritizing total cost of ownership analyses and prioritizing platforms that consolidate test menus to reduce unit costs. Meanwhile, reagent and kit providers are re-evaluating distribution agreements and exploring regional manufacturing partnerships to mitigate customs complexity and tariff exposure. The net effect is a renewed emphasis on supply chain resilience, strategic supplier relationships, and procurement practices that balance cost containment with the imperative of maintaining diagnostic quality and continuity of patient care.

Deep segmentation intelligence that connects diagnostic modalities, pathogen targets, end-user settings, sample requirements, platform technologies, and product categories into actionable market implications

Segmentation insights reveal differentiated demand drivers and technology fit across diagnostic modalities, pathogen targets, end-user settings, sample types, technology platforms, and product forms. Based on diagnostic test types, laboratory tests remain central for high-throughput biomarker-based, blood, and urine testing workflows, while molecular tests such as next-generation sequencing, nucleic acid amplification tests, and polymerase chain reaction deliver gold-standard sensitivity for complex pathogen detection. Point-of-care formats including portable analyzers, rapid diagnostic tests, and self-test kits are expanding access but require careful validation to ensure parity with laboratory methods.

Pathogen-focused segmentation identifies distinct clinical and commercial priorities across bacterial infections like chlamydia, gonorrhea, and syphilis; viral infections including hepatitis B, herpes simplex, HIV, and HPV; parasitic causes such as trichomoniasis; and fungal conditions like candidiasis. End-user segmentation highlights that diagnostic laboratories, including pathology and research labs, prioritize throughput and multiplex capability, whereas home care channels, through direct-to-consumer testing and online pharmacies, emphasize ease of use and clear guidance for follow-up. Hospitals and clinics balance rapid turnaround with integration into electronic medical records, and public health departments require robust reporting and surveillance interoperability.

Sample-type segmentation underscores that blood-derived plasma and serum, swab collections from genital, oral, and rectal sites, and urine samples including first-catch and midstream variants each impose unique pre-analytic controls and kit design considerations. Technology segmentation shows the growing relevance of CRISPR-based diagnostics, immunoassays such as ELISA and lateral flow, lab-on-a-chip microfluidics, and spectroscopy techniques including infrared and Raman for adjunctive analysis. Product-type segmentation differentiates consumables like pipettes and tubes, instruments such as analyzers and automation systems, and reagents and kits tailored for bacterial versus viral diagnostics, each with distinct procurement cycles and regulatory pathways. These intersecting segmentation layers inform go-to-market strategies, clinical validation priorities, and product development roadmaps.

Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence diagnostic adoption, access, and partnership models

Regional dynamics shape demand patterns, regulatory imperatives, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas region, clinical networks and public health agencies are deploying a mix of centralized laboratory platforms and expanding community-based testing to address persistent gaps in access and timely diagnosis. Meanwhile, coverage policies and evolving reimbursement frameworks influence the adoption cadence for novel molecular and point-of-care solutions.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and varying laboratory infrastructure drive differential adoption of high-complexity assays versus decentralized rapid tests. Public health priorities in this region emphasize surveillance, antimicrobial resistance monitoring, and equitable access, which creates demand for robust, low-cost diagnostics with strong field performance. In the Asia-Pacific region, manufacturing capacity, a large and diverse patient base, and rapid uptake of digital health integrations support accelerated adoption of integrated diagnostic platforms and localized production of reagents and consumables. Collectively, these regional characteristics inform market entry strategies, distribution partnerships, and the localization of service and support capabilities to meet specific clinical and regulatory requirements.

Competitive and collaborative company strategies that combine platform consolidation, regulatory reach, and innovative tech partnerships to win in STD diagnostics

Key company-level insights focus on strategic positioning, portfolio breadth, and capabilities that enable differentiation in a competitive diagnostics ecosystem. Leading instrument manufacturers emphasize platform consolidation, providing analyzers and automation systems that support multiplex testing and integrate with laboratory information systems. Reagent and kit providers focus on validated, pathogen-specific assays for bacterial and viral diagnostics while investing in supply chain robustness and regulatory registrations across multiple jurisdictions. Emerging players prioritize disruptive technologies such as CRISPR-based assays, lab-on-a-chip microfluidics, and novel spectroscopy approaches, seeking clinical validation partnerships and targeted pilot deployments to build credibility.

Channel and service models are increasingly important differentiators. Companies that offer flexible procurement options, training and technical support, and data-management services that facilitate reporting to public health authorities tend to achieve higher adoption in institutional settings. At the same time, organizations that develop clear pathways for consumer-facing products, including support for confirmatory testing and linkage to care, are better positioned to capture demand in home testing channels. Strategic collaborations between established manufacturers and innovative startups, including co-development and distribution agreements, are accelerating the translation of novel diagnostics into scalable offerings while mitigating technical and regulatory risk.

Practical and actionable strategic priorities for manufacturers, laboratories, and public health partners to accelerate adoption and build resilient diagnostic businesses

Industry leaders should pursue a set of coordinated actions that align product development, regulatory strategy, supply chain resilience, and commercial models to capture emerging opportunities. Prioritize investments in technologies that bridge laboratory-grade performance with decentralized usability so that platforms can be deployed across hospitals, community clinics, and consumer settings while maintaining clinical integrity. Simultaneously, establish clear evidence-generation plans that emphasize real-world performance, confirmatory pathways, and cost-effectiveness to support payer and procurement decisions.

Strengthening supplier diversity and nearshoring components where feasible will reduce exposure to tariff volatility and improve responsiveness to demand surges. Develop tiered go-to-market approaches that tailor messaging and support to diagnostic laboratories, hospitals, public health departments, and home care channels, and create bundled service offerings that include training, integration support, and data reporting capabilities. Finally, pursue strategic partnerships with public health agencies, academic centers, and technology innovators to accelerate validation studies and expand surveillance applications, thereby reinforcing clinical credibility and creating pathways to long-term adoption.

A rigorous mixed-methods research process combining practitioner interviews, technical literature review, and cross-validated analytical frameworks to ensure robust diagnostic insights

The research methodology for this report combined primary and secondary approaches to develop a comprehensive view of the sexually transmitted disease diagnostics landscape. Primary research included structured interviews and consultations with clinical laboratory directors, infectious disease clinicians, public health officials, and diagnostic industry executives to capture current practices, barriers to adoption, and strategic priorities. These firsthand perspectives informed qualitative assessments of technology readiness, operational constraints, and adoption drivers across clinical and consumer channels.

Secondary research reviewed peer-reviewed literature, regulatory guidance documents, conference proceedings, and product technical specifications to validate technology descriptions, sample handling requirements, and regulatory pathways. Cross-validation between primary and secondary inputs ensured that conclusions reflect both practitioner experience and the technical evidence base. Analytical frameworks emphasized technology maturity, clinical utility, supply chain factors, and commercialization dynamics. Wherever possible, evidence was triangulated across multiple sources to reduce bias and increase the robustness of insights included in the report.

Summative perspectives on how innovation, operational resilience, and strategic collaboration will determine which diagnostic offerings gain clinical traction and public health value

In conclusion, sexually transmitted disease diagnostics are at an inflection point where technological advances, evolving care models, and supply chain realities intersect to redefine clinical workflows and market opportunities. Innovations in molecular testing, CRISPR-based platforms, microfluidics, and enhanced immunoassays are expanding the capabilities of both centralized laboratories and decentralized testing environments. As a result, stakeholders must balance the promise of rapid, sensitive diagnostics with the practicalities of validation, regulatory compliance, and integration into care pathways.

Leaders who proactively align product development with end-user needs, fortify supply chains against tariff and sourcing shocks, and create partnerships that bridge clinical, public health, and consumer contexts will be best positioned to translate technological promise into sustained clinical impact. The actions recommended in this summary provide a strategic foundation to guide investment, collaboration, and operational decisions that will shape the future of STD detection and management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid point-of-care molecular assays in community health settings to reduce time to diagnosis
  • 5.2. Development of multiplexed testing platforms for simultaneous detection of multiple STDs including emerging pathogens
  • 5.3. Adoption of self-collection and at-home sampling kits for decentralized STD screening in high-risk populations
  • 5.4. Implementation of AI-driven data analytics for predictive modeling of STD outbreaks and personalized treatment strategies
  • 5.5. Increasing use of CRISPR-based diagnostics for highly sensitive and specific detection of chlamydia and gonorrhea
  • 5.6. Collaboration between telemedicine providers and diagnostic manufacturers to expand remote STD testing access
  • 5.7. Focus on antibiotic resistance detection assays to guide targeted therapy for drug-resistant gonorrhea infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexually Transmitted Disease Diagnostics Market, by Diagnostic Test Types

  • 8.1. Laboratory Tests
    • 8.1.1. Biomarker-Based Tests
    • 8.1.2. Blood Tests
    • 8.1.3. Urine Tests
  • 8.2. Molecular Tests
    • 8.2.1. Next-Generation Sequencing
    • 8.2.2. Nucleic Acid Amplification Tests (NAATs)
    • 8.2.3. Polymerase Chain Reaction (PCR)
  • 8.3. Point-of-Care Tests
    • 8.3.1. Portable Analyzers
    • 8.3.2. Rapid Diagnostic Tests
    • 8.3.3. Self-Test Kits

9. Sexually Transmitted Disease Diagnostics Market, by Pathogen Types

  • 9.1. Bacterial STDs
    • 9.1.1. Chlamydia
    • 9.1.2. Gonorrhea
    • 9.1.3. Syphilis
  • 9.2. Fungal STDs
    • 9.2.1. Candidiasis
  • 9.3. Parasitic STDs
    • 9.3.1. Trichomoniasis
  • 9.4. Viral STDs
    • 9.4.1. Hepatitis B
    • 9.4.2. Herpes Simplex Virus
    • 9.4.3. Human Immunodeficiency Virus (HIV)
    • 9.4.4. Human Papillomavirus (HPV)

10. Sexually Transmitted Disease Diagnostics Market, by End-User Types

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Pathology Laboratories
    • 10.1.2. Research Laboratories
  • 10.2. Home Care Settings
    • 10.2.1. Direct-to-Consumer Testing
    • 10.2.2. Online Pharmacies
  • 10.3. Hospitals and Clinics
    • 10.3.1. Healthcare Facilities
    • 10.3.2. Outpatient Clinics
  • 10.4. Public Health Departments
    • 10.4.1. Community Health Centers
    • 10.4.2. State Health Departments

11. Sexually Transmitted Disease Diagnostics Market, by Sample Types

  • 11.1. Blood Samples
    • 11.1.1. Plasma
    • 11.1.2. Serum
  • 11.2. Swab Samples
    • 11.2.1. Genital Swabs
    • 11.2.2. Oral Swabs
    • 11.2.3. Rectal Swabs
  • 11.3. Urine Samples
    • 11.3.1. First Catch
    • 11.3.2. Midstream

12. Sexually Transmitted Disease Diagnostics Market, by Technology Types

  • 12.1. CRISPR-Based Diagnostics
    • 12.1.1. CRISPR-Cas
  • 12.2. Immunoassays
    • 12.2.1. ELISA
    • 12.2.2. Lateral Flow Assays
  • 12.3. Microfluidics
    • 12.3.1. Lab-on-a-Chip
  • 12.4. Spectroscopy
    • 12.4.1. Infrared
    • 12.4.2. Raman Spectroscopy

13. Sexually Transmitted Disease Diagnostics Market, by Product Types

  • 13.1. Consumables
    • 13.1.1. Pipettes
    • 13.1.2. Tubes
  • 13.2. Instruments
    • 13.2.1. Analyzers
    • 13.2.2. Automation Systems
  • 13.3. Reagents and Kits
    • 13.3.1. Kits for Bacterial STDs
    • 13.3.2. Kits for Viral STDs

14. Sexually Transmitted Disease Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexually Transmitted Disease Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexually Transmitted Disease Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. Astra Biotech Gmbh
    • 17.3.3. Becton Dickinson and company
    • 17.3.4. Bio-Rad Laboratories, Inc.
    • 17.3.5. bioMerieux SA
    • 17.3.6. Danaher Corporation
    • 17.3.7. Daye Limited
    • 17.3.8. Diasorin S.p.A
    • 17.3.9. F. Hoffmann-La Roche Ltd
    • 17.3.10. Geneproof
    • 17.3.11. Hologic Inc.
    • 17.3.12. Jiangsu BioPerfectus Technologies Co., Ltd
    • 17.3.13. Liferiver Bio-Tech Corp.
    • 17.3.14. MedMira Inc
    • 17.3.15. Meridian Bioscience Inc.
    • 17.3.16. Mylab Discovery Solutions Pvt. Ltd.
    • 17.3.17. OraSure Technologies, Inc.
    • 17.3.18. Qiagen Inc
    • 17.3.19. Quest Consumer Inc.
    • 17.3.20. Sansure Biotech Inc.
    • 17.3.21. Seegene Inc.
    • 17.3.22. Siemens Healthcare GmbH
    • 17.3.23. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TRICHOMONIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2025-20